Canada
Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report
18 April 2024
Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.
NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
18 September 2023
In this report, we explore the potential impact of the National Institute of Health and Care Excellence (NICE) decision outcomes on healthcare decision-making in 12 countries across the globe (Australia, Brazil, Canada, France, Italy, Israel, Japan, South Korea, Poland, Saudi Arabia, Sweden, and the United Arab Emirates). We used quantitative and qualitative methods to estimate the level of impact and potential underlying mechanisms.
Are Recommendations for HTA of Gene Therapies Being Achieved?
11 September 2023
In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the…
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
1 February 2021
This research paper examines whether value of a life estimates used in economic evaluation differs between government departments in a selection of developed countries. The authors find that generally estimates used in transport and the environment exceeded those used in health, which suggests that health may be undervalued by departments of health compared to departments of transport or environment.
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin,…
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
5 January 2020
OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs).…
The Life Cycle of Pharmaceuticals: A Cross-National Perspective
1 April 2002
This study provides a life cycle perspective on cross-national differences in pharmaceutical prices, volumes and expenditures. Most previous studies have focused solely on cross-national differences in…
Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison
1 June 2000
Most countries regulate manufacturer prices for pharmaceuticals, either directly (France, Italy) or indirectly through controls on reimbursement (Germany, Japan) or profits (the UK). It is widely…